Skye Bioscience to Present Poster at Keystone Obesity Conference

Skye Bioscience (Nasdaq: SKYE) will present a poster at the Keystone Obesity conference on Jan 28, 2026 addressing nimacimab, a peripherally‑restricted CB1‑inhibitor antibody, in diet induced obesity models.

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE) will present a poster at the Keystone Obesity conference on Jan 28, 2026 addressing nimacimab, a peripherally‑restricted CB1‑inhibitor antibody, in diet induced obesity models.

Presentation covers nimacimab alone, combined with tirzepatide, durability after treatment stop, maintenance use post‑tirzepatide, and role of caloric restriction. Presenting author: Chris Twitty, PhD. Poster session 2, poster number 2020, at 7:30 PM.

Argus Jan 21 session

+0.79% close to close Open Argus

Details

News Market Reaction – SKYE

On Jan 21, the day this news came out, SKYE closed 0.79% above the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Key Figures

Poster session: 2 Poster number: 2020 Presentation date: 1/28/2026 +1 more

Poster session

2

Keystone Obesity Therapeutics conference session number

Poster number

2020

Nimacimab obesity poster identifier at Keystone conference

Presentation date

1/28/2026

Scheduled date of Keystone obesity poster presentation

Presentation time

7:30:00 PM

Scheduled time of Keystone obesity poster presentation

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Corporate outlook

   24h Move

   -4.0%

   Outlined 2026 nimacimab milestones and development plans.

2. Jan 05

   Collaboration deal

   24h Move

   -2.3%

   Halozyme ENHANZE license for higher-dose nimacimab delivery.

3. Nov 24

   Investor conferences

   24h Move

   +11.6%

   Participation in multiple December healthcare investor conferences.

4. Nov 10

   Earnings & trial

   24h Move

   -7.2%

   Q3 2025 results and CBeyond Phase 2a combination data update.

5. Nov 05

   Clinical data

   24h Move

   +6.3%

   Late-breaking ObesityWeek oral on rebound weight gain data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

peripherally-restricted cb1-inhibitor antibody, incretin agonists, tirzepatide, diet induced obesity (dio) mouse model

4 terms

peripherally-restricted cb1-inhibitor antibody medical

"the ability of its peripherally-restricted CB1-inhibitor antibody"

A peripherally-restricted CB1-inhibitor antibody is a biologic drug designed to block CB1 receptors that sit on cells outside the brain, while being kept out of the central nervous system by the blood–brain barrier. Think of it as a targeted blocker that treats conditions like metabolic disease or pain at the body’s periphery without affecting brain signaling, which can improve safety and broaden market appeal for investors watching efficacy, side-effect profiles, and regulatory risk.

incretin agonists medical

"Can nimacimab enhance optimal and suboptimal doses of incretin agonists?"

Incretin agonists are drugs that copy natural gut hormones released after a meal to boost insulin release and help lower blood sugar. They matter to investors because they can significantly change treatment patterns and company revenues—think of a hit product that reshapes an industry—by driving sales growth, altering prescription trends, and affecting healthcare costs and competition in the diabetes and weight-management markets.

tirzepatide medical

"Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?"

Tirzepatide is a prescription medicine that helps lower blood sugar and reduce appetite by activating two hormones that regulate insulin and hunger; think of it as a two-in-one switch that calms the body’s sugar spikes and decreases cravings. Investors watch it because regulatory approvals, clinical results, pricing and patient demand determine sales potential and competitive impact on companies in diabetes and obesity treatment markets.

diet induced obesity (dio) mouse model medical

"Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model"

A diet induced obesity (DIO) mouse model is an early-stage laboratory test in which mice are fed a high-calorie diet until they develop weight gain and related metabolic changes, creating a controlled stand-in for human obesity. Investors pay attention because results from these tests act like a prototype check—showing whether a drug, device, or treatment can work and appear safe before costly human trials, which influences development timelines and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.

Skye’s presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:

• Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
• How durable is nimacimab’s effect on weight loss after treatment discontinuation?
• Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?
• Is caloric-restriction the primary mechanism of nimacimab-driven weight loss?

Presentation details:

Title: Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model
Presenting Author: Chris Twitty, PhD
Poster Session: 2
Poster Number: 2020
Date: 1/28/2026
Time: 7:30:00 PM

About Nimacimab

Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has also demonstrated additive or complementary effects in combination with incretin-based therapies in preclinical and clinical studies.

Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

CONTACTS

Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Skye Bioscience (SKYE) present the nimacimab poster at Keystone Obesity on January 28, 2026?

The poster is scheduled for Jan 28, 2026 at 7:30 PM in Poster Session 2 (Poster Number 2020).

What questions will Skye Bioscience (SKYE) address about nimacimab in the Keystone poster?

The poster examines nimacimab alone or with tirzepatide, durability after discontinuation, use as maintenance post‑tirzepatide, and whether caloric restriction drives weight loss.

Who is the presenting author for Skye Bioscience's (SKYE) Keystone Obesity poster?

The presenting author is Chris Twitty, PhD.

What is the title of Skye Bioscience's (SKYE) poster at Keystone Obesity on 1/28/2026?

Title: Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model.

Which compound combinations does Skye Bioscience (SKYE) test in the Keystone poster?

The poster tests nimacimab alone and in combination with tirzepatide in a DIO mouse model.